Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.40 |
| ▸ | HTR3A | P46098 | 4/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185662 | 0.85 | KDM4C (0.39) | PTGER4MEN1KMT2AHTT | |
| SCHEMBL14185660 | 0.85 | NAMPT (0.38) | PTGER4MAPTALDH1A1LMNA | |
| SCHEMBL14185466 | 0.85 | TUBB4A (0.35) | PTGER4MEN1KMT2AHTT | |
| SCHEMBL13758173 | 0.82 | PTGER4 (0.49) | PTGER4NPY5RMEN1KMT2ASLC6A2 | |
| SCHEMBL14185158 | 0.81 | HTT (0.47) | NPY5RMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL24482623 | 0.80 | PABPC1 (0.51) | PTGER4NPY5RMEN1KMT2ASLC6A2 | |
| Maleic Acid SCHEMBL4496354 | 0.77 | SLC6A2 (0.55) | PTGER4NPY5RMEN1KMT2ASLC6A2 | |
| Fumaric Acid SCHEMBL4496356 | 0.77 | SLC6A2 (0.55) | PTGER4NPY5RMEN1KMT2ASLC6A2 | |
| SCHEMBL4339606 | 0.76 | MAP4K4 (0.47) | PTGER4MEN1KMT2AMAPTALDH1A1 | |
| Fumaric Acid SCHEMBL8051638 | 0.71 | SLC6A2 (0.48) | PTGER4MEN1KMT2ASLC6A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501797-B1 | 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | IL4, STAT4, STAT6 | PTGER4 157/4885HTR3A 1091/4885NPY5R 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.